← Leaderboards
Elizabeth Ann Sugar
Johns Hopkins University
$11,501,247
Attributed
$34,868,302
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2018–24$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$34,868,302 · 4
By mechanism
U01$25,153,102 · 1
UG1$9,004,458 · 1
R21$387,486 · 1
P50$323,256 · 1
Top collaborators
- Mercedes Renee Carnethon7 shared
- Ravi Kalhan7 shared
- George R Washko7 shared
- Janet T. Holbrook5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Janet T. Holbrook$51,624,279
- Douglas A Jabs$24,554,490
- Robert A. Wise$33,179,807
- Meredith C McCormack$14,784,022
- Michelle A Petri$20,289,441
Others in their field
Other Emerging Leaders on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$211,662,224
Research focus
BaseResearch PersonnelChronicCohortParticipantFuturePublishingTranslatingResponseClinical ResearchBiological MarkersLongitudinal StudiesBioinformaticsCommunitiesRisk FactorsRespiratoryRecruitEvaluationStatistical Data InterpretationSuccessReportingPublicationsResourcesAmerican Lung Association
Grant awards (17)
The American Lung Association (ALA) Lung Health Cohort$4,111,293
U01 · FY2024 · HL
The American Lung Association (ALA) Lung Health Cohort$4,746,866
U01 · FY2023 · HL
The American Lung Association (ALA) Lung Health Cohort$4,109,258
U01 · FY2022 · HL
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$972,337
UG1 · FY2022 · EY
The American Lung Association (ALA) Lung Health Cohort$4,192,016
U01 · FY2021 · HL
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$2,640,821
UG1 · FY2021 · EY
The American Lung Association (ALA) Lung Health Cohort$4,726,167
U01 · FY2020 · HL
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$2,717,020
UG1 · FY2020 · EY
The American Lung Association (ALA) Lung Health Cohort$436,313
U01 · FY2020 · HL
Leveraging long-term follow-up in the MUST Trial and Follow-up Study: Remission, Ocular outcomes and Quantifying utility in patients with severe uveitis (MUST-ROQ)$206,243
R21 · FY2020 · EY · contact PI
Core 1: Biostatistics Core$106,630
P50 · FY2020 · CA · contact PI
The American Lung Association (ALA) Lung Health Cohort$2,831,189
U01 · FY2019 · HL
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$1,915,534
UG1 · FY2019 · EY
Leveraging long-term follow-up in the MUST Trial and Follow-up Study: Remission, Ocular outcomes and Quantifying utility in patients with severe uveitis (MUST-ROQ)$181,243
R21 · FY2019 · EY · contact PI
Core 1: Biostatistics Core$104,385
P50 · FY2019 · CA · contact PI
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$758,746
UG1 · FY2018 · EY
Core 1: Biostatistics Core$112,241
P50 · FY2018 · CA · contact PI